Qlife Holding AB (publ) (QLIFE.ST)
SEK 1.9
(-1.81%)
SEK 1.9
(-1.81%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 19.07 Million SEK | -49.68% |
| 2022 | 37.89 Million SEK | 154.32% |
| 2021 | -69.75 Million SEK | -313.66% |
| 2020 | -16.86 Million SEK | -11598.08% |
| 2019 | 146.66 Thousand SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 5.28 Million SEK | -72.31% |
| 2024 Q2 | 7.87 Million SEK | 49.11% |
| 2023 Q4 | 19.07 Million SEK | 240.9% |
| 2023 Q2 | -1.85 Million SEK | -103.22% |
| 2023 FY | 19.07 Million SEK | -49.68% |
| 2023 Q1 | 57.62 Million SEK | 52.08% |
| 2023 Q3 | 5.59 Million SEK | 401.56% |
| 2022 Q1 | -38.6 Million SEK | 44.66% |
| 2022 FY | 37.89 Million SEK | 154.32% |
| 2022 Q2 | 24.01 Million SEK | 162.2% |
| 2022 Q3 | 59 Million SEK | 145.74% |
| 2022 Q4 | 37.89 Million SEK | -35.78% |
| 2021 FY | -69.75 Million SEK | -313.66% |
| 2021 Q1 | 10.11 Million SEK | 160.0% |
| 2021 Q3 | -79.21 Million SEK | 23.96% |
| 2021 Q4 | -69.75 Million SEK | 11.94% |
| 2021 Q2 | -104.17 Million SEK | -1129.63% |
| 2020 Q1 | -33.72 Million SEK | -23092.75% |
| 2020 Q2 | -27.58 Million SEK | 18.19% |
| 2020 FY | -16.86 Million SEK | -11598.08% |
| 2020 Q4 | -16.86 Million SEK | -4.7% |
| 2020 Q3 | -16.1 Million SEK | 41.62% |
| 2019 FY | 146.66 Thousand SEK | 0.0% |
| 2019 Q4 | 146.66 Thousand SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Acarix AB (publ) | -35.14 Million SEK | 154.255% |
| ADDvise Group AB (publ) | 1.22 Billion SEK | 98.446% |
| ADDvise Group AB (publ) | 1.22 Billion SEK | 98.446% |
| Arcoma AB | -1.12 Million SEK | 1790.603% |
| Bactiguard Holding AB (publ) | 109.88 Million SEK | 82.645% |
| BICO Group AB (publ) | 927.9 Million SEK | 97.945% |
| Boule Diagnostics AB (publ) | 128.8 Million SEK | 85.194% |
| CellaVision AB (publ) | -56.94 Million SEK | 133.49% |
| Clinical Laserthermia Systems AB (publ) | -14.87 Million SEK | 228.184% |
| Chordate Medical Holding AB (publ) | -8.45 Million SEK | 325.541% |
| C-Rad AB (publ) | -127.6 Million SEK | 114.945% |
| Duearity AB (publ) | 10.23 Million SEK | -86.394% |
| Dignitana AB (publ) | 13.07 Million SEK | -45.829% |
| Episurf Medical AB (publ) | -52.7 Million SEK | 136.186% |
| Getinge AB (publ) | 5.4 Billion SEK | 99.647% |
| Scandinavian Real Heart AB (Publ) | -35.05 Million SEK | 154.403% |
| Iconovo AB (publ) | -10.75 Million SEK | 277.307% |
| Integrum AB (publ) | -10.47 Million SEK | 282.026% |
| Luxbright AB (publ) | -13.83 Million SEK | 237.854% |
| Mentice AB (publ) | -49.56 Million SEK | 138.476% |
| OssDsign AB (publ) | -162.78 Million SEK | 111.715% |
| Paxman AB (publ) | -11.41 Million SEK | 267.119% |
| Promimic AB (publ) | -50.32 Million SEK | 137.895% |
| SciBase Holding AB (publ) | -27.32 Million SEK | 169.792% |
| ScandiDos AB (publ) | -1.53 Million SEK | 1345.591% |
| Sectra AB (publ) | -772.85 Million SEK | 102.467% |
| Sedana Medical AB (publ) | -226.87 Million SEK | 108.406% |
| Senzime AB (publ) | -139.54 Million SEK | 113.666% |
| SpectraCure AB (publ) | -50.23 Million SEK | 137.962% |
| Stille AB | -178.5 Million SEK | 110.683% |
| Vitrolife AB (publ) | 1.22 Billion SEK | 98.447% |
| Xvivo Perfusion AB (publ) | -214.65 Million SEK | 108.884% |